Diagnostics
Cipla announces the launch of Daptomycin for Injection, 500 mg/vial, single-dose vials
(for intravenous use only)
Mumbai, India, & New Jersey, USA; 25th September, 2019: Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”) announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States.
According to IQVIA (IMS Health), Cubicin® for Injection (daptomycin for injection) had U.S. sales of approximately $606 Million for the 12-month period ending June 2019. The product is available for shipping immediately.
Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.